BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 11182745)

  • 41. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Autoantibodies, immunoglobulins and cytokine profile in patients with graves' disease and Graves' orbitopathy].
    Sviridenko NY; Bessmertnaya EG; Belovalova IM; Mikheenkov AA; Sheremeta MS; Nikankina LV; Malysheva NM
    Probl Endokrinol (Mosk); 2020 Oct; 66(5):15-23. PubMed ID: 33369369
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial.
    Brammen L; Riss P; Lukas J; Gessl A; Dunkler D; Li S; Leisser A; Rezar-Dreindl S; Eibenberger K; Selberherr A; Scheuba C; Papp A
    Trials; 2018 Sep; 19(1):495. PubMed ID: 30219088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Similarity and dissimilarity between clinical and laboratory findings, especially anti-thyrotropin receptor antibody in ophthalmic Graves' disease without persistent hyperthyroidism and hyperthyroid Graves' disease.
    Kosugi S; Inoue D; Sugawa H; Enomoto T; Mori T; Imura H
    Endocrinol Jpn; 1990 Jun; 37(3):343-54. PubMed ID: 2253584
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Influence of glucocorticoid therapy on intratherapeutic biodistribution of 131I radioiodine therapy in Graves' disease].
    Halstenberg J; Kranert WT; Korkusuz H; Mayer A; Ackermann H; Grünwald F; Happel C
    Nuklearmedizin; 2018 Apr; 57(2):43-49. PubMed ID: 29590674
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Severe Graves' ophthalmopathy after percutaneous ethanol injection in a nontoxic thyroid nodule.
    Regalbuto C; Le Moli R; Muscia V; Russo M; Vigneri R; Pezzino V
    Thyroid; 2012 Feb; 22(2):210-3. PubMed ID: 22196093
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy].
    Bossowski A; Stasiak-Barmuta A; Urban M; Rinderle C
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2004; 10(2):93-101. PubMed ID: 15504312
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.
    Gunji K; De Bellis A; Kubota S; Swanson J; Wengrowicz S; Cochran B; Ackrell BA; Salvi M; Bellastella A; Bizzarro A; Sinisi AA; Wall JR
    J Clin Endocrinol Metab; 1999 Apr; 84(4):1255-62. PubMed ID: 10199764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Remission of Graves' hyperthyroidism and A/G polymorphism at position 49 in exon 1 of cytotoxic T lymphocyte-associated molecule-4 gene.
    Kinjo Y; Takasu N; Komiya I; Tomoyose T; Takara M; Kouki T; Shimajiri Y; Yabiku K; Yoshimura H
    J Clin Endocrinol Metab; 2002 Jun; 87(6):2593-6. PubMed ID: 12050220
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
    Bossowski A; Stasiak-Barmuta A; Urban M
    Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of thyrotropin and thyrotropin-receptor-stimulating Graves' disease immunoglobulin G on cyclic adenosine monophosphate and hyaluronan production in nondifferentiated orbital fibroblasts of Graves' ophthalmopathy patients.
    van Zeijl CJ; Fliers E; van Koppen CJ; Surovtseva OV; de Gooyer ME; Mourits MP; Wiersinga WM; Miltenburg AM; Boelen A
    Thyroid; 2010 May; 20(5):535-44. PubMed ID: 20384487
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
    Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced Retinal Microvascular Density Related to Activity Status and Serum Antibodies in Patients with Graves' Ophthalmopathy.
    Wu Y; Tu Y; Bao L; Wu C; Zheng J; Wang J; Lu F; Shen M; Chen Q
    Curr Eye Res; 2020 May; 45(5):576-584. PubMed ID: 31595798
    [No Abstract]   [Full Text] [Related]  

  • 55. Increased plasma levels of soluble programmed death ligand 1 (sPD-L1) and fibroblast growth factor 23 (FGF-23) in patients with Graves' ophthalmopathy in comparison to hyperthyroid patients without Graves' ophthalmopathy.
    Khamisi S; Anders Karlsson F; Ljunggren Ö; Thulin M; Larsson A
    Cytokine; 2023 Sep; 169():156269. PubMed ID: 37307688
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
    Woo YJ; Jang SY; Lim TH; Yoon JS
    Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Comparison of the effectiveness of 131-I and antithyroid drugs in the treatment of Graves' disease in children].
    Chen DY; Chen TH
    Zhonghua Er Ke Za Zhi; 2005 Jul; 43(7):507-9. PubMed ID: 16083551
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
    Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
    Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Soluble intercellular adhesion molecule-1 concentrations in patients with subacute thyroiditis and in patients with Graves' disease with or without ophthalmopathy.
    Ozata M; Bolu E; Sengül A; Altinsoy HI; Turan M; Corakci A; Hacibektasoglu A; Gundogan MA
    Endocr J; 1996 Oct; 43(5):517-25. PubMed ID: 8980891
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Increased retinal blood flow in patients with active Graves' ophthalmopathy.
    Perri P; Campa C; Costagliola C; Incorvaia C; D'Angelo S; Sebastiani A
    Curr Eye Res; 2007 Nov; 32(11):985-90. PubMed ID: 18027174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.